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Introduction
The use of living, disaggregated cells in medicine in-
volves a number of aspects that make this approach
distinct from traditional pharmaceutical products. Cells
are not metabolized by the liver or kidney, unlike most
small-molecule drugs, but are potentially capable of
distribution throughout the entire body. Cells are also
highly complex and change dynamically in response
to their environment and over time, making it diffi-
cult to standardize them in the same way that molecules
can be engineered and mass-produced. Some type of
cells may also secrete multiple bioactive molecules,
such as cytokines and growth factors, as well as
microvesicles, which may be released in different
amounts or combinations, depending upon the cells’
immediate environment or the pathophysiological state
of the body into which they are introduced.
These properties of heterogeneity, complexity and
malleability can make it challenging to test cell-
based products through the use of paradigms developed
for highly standardized and stable molecular products.
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This does not, however, mean that it is impossible to
determine the safety and clinical usefulness of such
products, nor does it remove the responsibility to
provide rigorous, independently verifiable evidence
from those who seek to develop cell-based interven-
tions for commercialization or use in standard of care
[1].
Therefore, the clinical translation of cell-based re-
search toward development of specific therapies for
a variety of diseases faces several challenges, not dis-
similar to what took place in the 1990s during the
early manufacturing of monoclonal antibodies for
therapeutic uses [2]. After proper and rigorous as-
sessments, these therapies are now used clinically for
several diseases, with good success for large numbers
of patients.
Next to (i) challenges related to the choice of a
characterized cell type; (ii) understanding of its po-
tential mechanisms of action for a specific disease; (iii)
the technical aspects of its isolation, characterization
and possible expansion under appropriate current
GoodManufacturing Practice (cGMP) conditions; (iv)
dose, dosing and mode of administration for any given
clinical indication; and (v) the pre-clinical disease
models in which to confirm proof of principle, it is
crucial to define what evidence is needed to con-
clude that a particular therapy is safe and efficacious
and can be considered as “standard of care,” or at least
a legitimate and viable option for that particular con-
dition.Whereas the scientific aspects of this process
can be reasonably defined, and should indeed be
uniform worldwide, medical, regulatory, social and
ethical aspects vary with respect to actual implemen-
tation of these approaches. These issues must be
addressed to help the development of these thera-
pies [3].
The scientific principles and the path required to
move toward the goal of finding safe and effective cell
therapies are reasonably well defined [4]. Initially, this
involves developing proof-of-concept with both in vitro
work and appropriate pre-clinical animal models, using
clearly defined cells. Subsequent steps then include
moving on to well-designed and monitored clinical
studies with cells substantially or non-substantially ma-
nipulated through the use of reproducible methods
under classified conditions. Clear documentation of
defined and measureable outcomes that can estab-
lish unequivocal safety and efficacy must be included.
Importantly, there should also be proper follow-up to
provide proof of long-term safety. We also advocate
that mechanistic studies be built into clinical inves-
tigations to provide further information to uncover and
validate potential mechanisms of action of the cells
introduced in a given disease [5].
One increasingly common approach is to offer au-
tologous therapies in which cells are harvested from
a patient’s own bone marrow, adipose or other tissues
and then are reinfused into the patient. Although this
is perhaps less problematic in terms of safety issues,
efficacy of such therapies must be evaluated by well-
defined and measurable parameters. It is also important
that long-term studies be performed for each poten-
tial clinical use.There is often little or no justification
for claims of efficacy used to lure patients into
undergoing these therapies. Furthermore, these ap-
proaches are most often done outside of legitimate
clinical trials, without defined measurements of out-
comes or adequate follow-up, and patients often pay
large and unreasonable sums of money to undergo
them [6].
“In case of emergency”: compassionate use of
cell therapies
At the same time, it is also recognized that in medical
emergencies or other difficult medical situations that
have exhausted other treatment options, the use of
cell-based therapies may be implemented on a
compassionate-use basis. Whereas regulations sur-
rounding this vary in different countries, they must
be applied in each situation with appropriate rigor. Fur-
thermore, if a compassionate-use approach is found
to be safe and consistently effective in any given disease,
these instances should lead to the development of clin-
ical trial protocols appropriate for that condition. Data
from such trials will then be subjected to appropri-
ate sharing and peer review.
The concept of “medical innovation” has been an
important approach in the history of medicine for de-
veloping innovative therapies, but it still has to work
within certain safeguards [3,7]. A system must exist
within institutions that consider such approaches.This
should rely on a physician presenting the need for such
a therapy for a patient who has run out of options.
An appropriate oversight committee then will be in
place to assess this scientific rationale and the poten-
tial clinical benefit.This also must include a process
to ensure that the patient or legal representatives have
understood the unproven nature of such a therapy and
to provide appropriate voluntary informed consent.
It must also be ensured that the concerned physi-
cian or institutions have no conflicts of interest in
promoting such therapies.Very importantly, no more
than a few patients may be treated this way, after which
a clinical trial protocol must be established if that par-
ticular approach must be continued.
If these principles can be followed universally, many
of the current problems with unauthorized and ille-
gitimate use of cell-based therapies may be avoided.
However, the easy access to certain types of cells, fre-
quently autologous mesenchymal stromal cells or
immune cells, the unmet medical needs of desperate
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patients and their families seeking care and potential
for cure, as well as the business potential and finan-
cial gain from these interventions, have all led to a large
and increasing number of centers around the world
that offer cell therapies that are yet to be established
as safe and effective to patients.
Needs and challenges of generating data on unproven
cell therapies
The next important issue to address is the amount of
data on clinical efficacy needed before a therapy may
be considered to be of proven value for that condi-
tion.As with any other new potential therapeutic agent,
this would require an initial well-designed and well-
regulated phase (Phase 1) study assessing initial safety
and feasibility studies that include attempts at defin-
ing appropriate doses to be used. These would then
be followed by studies on efficacy and further safety
studies (Phases 2 and 3), preferably in comparison to
the best existing therapies, if any. Depending on the
condition being treated, the selected end points, the
sample size, and the trial design will vary, and the result
would determine the status of that therapy.
In ideal circumstances, any new treatment would
be considered to be not only effective but also the
standard of care if it has been compared and found
to be superior to the current best option in an ade-
quately powered randomized trial. A parallel outcome
would be that the new treatment is found to be not
inferior to the current standard of care and thus be
available as a legitimate alternative therapeutic ap-
proach.As mandated by the regulatory agencies in each
country, there is no reason why these standards should
not be uniformly applied worldwide for develop-
ment of cell therapies.
We also acknowledge that in some ultra-rare, still-
lethal conditions, large, sufficiently powered, Phase 3
randomized cell-based clinical trials, using reliable and
valid primary end points, are not always feasible. For
these situations, the scientific community, the health-
care providers and the regulatory agencies should allow
early access to new therapies, including cell-based
therapies. In such cases, a risk-based assessment should
be taken into account that combines patient progno-
sis and safety aspects on manufacturing and delivery,
with sufficient peer-reviewed scientific evidence of ef-
ficacy.A good example is the first gene therapy product
that has been given market authorization by the Eu-
ropean Medical Agency (EMA), an adeno-associated
virus vector–based product for lipoprotein lipase de-
ficiency [8].
Additional issues may arise from the way the cells
are harvested and handled ex vivo, such as the case
of the so-called, non-substantially manipulated au-
tologous cells [9].The debate on the topic continues
as to whether these should be considered as medic-
inal products when utilized for non-homologous uses
[10,11]. Regardless of autologous versus allogeneic
use, or use of non-manipulated or manipulated cell
products, it is imperative to generate rigorous peer-
reviewed scientific evidence on their safety and efficacy
and subsequent review by proper regulatory authori-
ties before they can be used as medical treatment.
Nevertheless, a regulatory agency (EMA) claims, “The
Committee of AdvancedTherapy classification is based
on existing scientific knowledge of cell biology. Clas-
sification may vary according to the evolution of
science.” This suggests a framework for logical pro-
gression in which clinical development will follow
and inform peer-reviewed science, and vice versa, in
a mutually constructive relationship for the patient’s
benefit.
Challenges arise within these models at different
levels and in different countries. If there is no system
to support such a graded development process or if
there is no access to the current standard of care in
certain parts of the world, it will be difficult to
apply the principles described above. Social and
ethical issues with regard to access to some or any
care may then come into the decision-making process
for the approach to the development of these thera-
pies in those countries. While making adjustments
for those circumstances, it is critical to have indepen-
dent review mechanisms of the process to ensure that
the driving force is the concern for the patient and
not any conflict of interest on the part of the physi-
cian or the institution.Going forward, the data acquired
from such innovations must be peer reviewed, and a
clear regulatory path should be devised for the further
development and approval of these therapies [12].
Data should be reviewed by peers to decide when
such a therapy may be considered to be adequately
safe and effective as an option of treatment outside
of clinical trials or indeed become the standard of
care or a viable parallel approach. Depending on the
disease and the type of cell therapy treatment, this
could be done at the local or international level. As
such, there is significant potential for cell-based ther-
apeutic opportunities for a range of diseases, but only
if investigated and validated in the most rigorous
manner.
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